Economic consequences of the maximum allowable cost program to the entire profession of pharmacy.
D004345:Drug Industry; D005252:Fees, Pharmaceutical / Q000331:legislation & jurisprudence*; D007348:Insurance, Health / Q000331:legislation & jurisprudence*; D007349:Insurance, Health, Reimbursement / Q000331:legislation & jurisprudence*; D007356:Insurance, Pharmaceutical Services / Q000331:legislation & jurisprudence; D007880:Legislation, Drug; D010604:Pharmacy; D013810:Therapeutic Equivalency; D014481:United States